Key Highlights
- KRESLADI received FDA accelerated approval as a gene therapy treatment for pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I).
- Shares of RCKT surged up to 9% during premarket hours on Friday and maintained approximately 6% gains at market open.
- This marks the inaugural FDA-approved gene therapy specifically designed for severe LAD-I, a critical and rare immune disorder affecting children.
- Rocket Pharmaceuticals received a Rare Pediatric Disease Priority Review Voucher from the FDA, which the biotech intends to sell.
- The greenlight follows a resubmission after the FDA requested additional data following an initial rejection in June 2024.
Rocket Pharmaceuticals celebrated a significant regulatory victory on Friday as the FDA granted approval for its gene therapy KRESLADI, propelling RCKT shares upward by as much as 9% during premarket hours before stabilizing around a 6% gain at the opening bell.
Rocket Pharmaceuticals, Inc., RCKT
The regulatory green light came through the accelerated approval pathway, which relies on preliminary clinical evidence—in this case, elevated neutrophil CD18 and CD11a surface expression levels. The treatment’s full clinical benefits will require verification through extended data collection from an active clinical trial and a mandatory post-approval patient registry.
#NEWS: Rocket Pharmaceuticals today announced the U.S. FDA approval of the first #GeneTherapy for pediatric patients with severe Leukocyte Adhesion Deficiency-I (LAD-I).
More: https://t.co/YrJuWo1r3J pic.twitter.com/LkioRrrR5S
— Rocket Pharmaceuticals (@RocketPharma) March 27, 2026
KRESLADI, scientifically designated as marnetegragene autotemce, represents an autologous hematopoietic stem cell-based gene therapy. The FDA has authorized its use in pediatric patients diagnosed with severe LAD-I resulting from biallelic variants in the ITGB2 gene, specifically those without access to an HLA-matched sibling donor for conventional stem cell transplantation.
LAD-I stands as an exceptionally rare inherited immunodeficiency disorder. The condition triggers persistent infections and presents significant mortality risk during early childhood when left untreated. Within the United States, the disease occurs in approximately one out of every 100,000 to 200,000 live births, with severe cases accounting for roughly two-thirds of all diagnoses.
KRESLADI now holds the distinction of being the first gene therapy to receive FDA clearance for this particular condition.
The path to approval encountered obstacles along the way. The FDA initially declined the biologics license application in June 2024, requesting that Rocket provide supplementary data before proceeding with regulatory review.
Rocket responded by resubmitting the BLA, which the FDA accepted in October 2024, establishing March 28, 2026 as the goal action date—a timeline the regulatory agency successfully honored.
Priority Review Voucher Provides Additional Financial Benefit
Accompanying the approval, the FDA awarded Rocket a Rare Pediatric Disease Priority Review Voucher. Such vouchers carry substantial monetary value, often commanding hundreds of millions of dollars when transferred to other pharmaceutical manufacturers, representing a considerable financial advantage beyond the approval itself.
Rocket indicated it will assess opportunities to sell the voucher to strengthen its financial position.
“The approval of KRESLADI represents an important milestone for the severe LAD-I community,” said CEO Gaurav Shah.
Scientific Foundation Behind the Therapy
The research underpinning KRESLADI’s clinical development received partial funding support from the California Institute for Regenerative Medicine. The therapeutic approach focuses on the ITGB2 gene, which produces a critical protein enabling white blood cells to combat infections effectively.
The Cranbury, New Jersey-headquartered biotechnology company has dedicated multiple years pursuing this regulatory milestone.
The FDA’s designated action date for the resubmitted BLA was March 28, 2026, and the regulatory body delivered its approval precisely as scheduled.
